The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: A comprehensive review

Cardiology in Review

Volumn 18, Issue 6, 2010, Pages 298-304

  Mihos, Christos G ^b   Salas, Maria J ^b   Santana, Orlando ^a  

^a Mount Sinai Cancer Center   (United States)

^b NONE

Author keywords

Cardiovascular effects; HMG CoA inhibitors; pleiotropic; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; AORTA STENOSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; DEFIBRILLATOR; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; PERIPHERAL VASCULAR DISEASE; PLEIOTROPY; REVIEW; STROKE;

ACUTE CORONARY SYNDROME; AORTIC ANEURYSM, ABDOMINAL; AORTIC VALVE STENOSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLAMMATION; INTRACRANIAL HEMORRHAGES; VENOUS THROMBOEMBOLISM;

EID: 77958541531     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181f52a7f     Document Type: Review

References (108)

1. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 2000;321:983-985.
2. Tonkin A, Aylward P, Colquhoun D, et al. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
3. Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005;25:1093-1110.
4. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18.
5. Li J, Li JJ, He JG, et al. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway. Cardiovasc Ther. 2010;28:8-14.
6. Tandon V, Bano G, Khajuria V, et al. Pleiotropic effects of statins. Indian J Pharmacol. 2005;37:77-85.
7. Rosenson RS, Brown AS. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr Opin Lipidol. 2002;13:625-630.
8. Link A, Ayadhi T, Böhm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J. 2006;27:2945-2955.
9. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
10. Rodés-Cabau J, Tardif JC, Cossette M, et al. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol. 2009;104:750-757.
11. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
12. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405-1410.
13. Bavry AA, Mood GR, Kumbhani DJ, et al. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs. 2007;7: 135-141.
14. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850-1859.
15. Barrios V, Escobar E. Rosuvastatin along the cardiovascular continuum: from Jupiter to Aurora. Expert Rev Cardiovasc Ther. 2009;7:1317-1327.
16. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreased QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail. 2005;11:684-690.
17. Xie RQ, Cui W, Liu F, et al. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol. 2010;140:255-257.
18. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol. 2009;104:1708-1716.
19. McMurray JJ, Kjekshus J, Gullestad L, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation. 2009;120:2188-2196.
20. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573-578.
21. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119:48-53.
22. Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007;99:1448-1450.
23. Muhlhauser U, Zolk O, Rau T, et al. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J. 2006;20:785-787.
24. Okazaki H. Statin prevents structural and electrical remodeling in rat hypertensive heart failure induced by chronic inhibition of NO synthesis. Circulation. 2007;116(suppl):II-140.
25. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004;62:105-111.
26. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92:1379-1383.
27. Kulik A, Singh JP, Levin R, et al. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol. 2010;105:1655-1660.
28. Siu C, Lau C, Tse H. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92:1343-1345. (Pubitemid 37431149)
29. Sun YF, Mei YQ, Ji Q, et al. Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Zhonghua Yi Xue Za Zhi. 2009;89:2988-2991.
30. Vedre A, Gurm H, Froehlich J, et al. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009;104:1613-1617.
31. Pedersen TR. Overview of clinical trials on calcific aortic stenosis. Eur Heart J. 2008;10(suppl):E31-E40.
32. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205-2209.
33. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular stenosis in older persons. Am J Cardiol. 2001;88:693-695. (Pubitemid 32831111)
34. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723-1730.
35. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
36. Cowell SJ, Newby DE, Prescott RJ, et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Eng J Med. 2005;352:2389-2397.
37. Rossebo AB, Pedersen TR, Boman K, et al. for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. NEng JMed. 2008;359:1343-1356.
38. Chan KL, Teo K, Dumesnil JG, et al. ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
39. Griffin B. The Effect of Statin Therapy (Atorvastatin) on the Progression of Calcific Valvular Aortic Stenosis. The Cleveland Clinic. Clinicaltrial gov NCT00590135.
40. Sanchez P. Double Blind Randomized Phase IV Clinical Trial to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in the Haemodynamic Progression of Degenerative Aortic Stenosis. Hospital Universitario Grego-rio Maranón de Madrid. The AORTICA 1 Study.
41. Walther C. Statin Therapy in Asymptomatic Aortic Stenosis. University of Leipzig. Clinicaltrial gov: NCT00176410.
42. Desai H, Aronow WS, Tsai FS, et al. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter- defibrillator therapy. J Cardiovasc Pharmacol Ther. 2009;14:176-179.
43. Desai H, Aronow WS, Ahn C, et al. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. J Cardiovasc Pharmacol Ther. 2010;15:37-40.
44. Lai HM, Aronow WS, Kruger A, et al. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2008;102:77-78.
45. Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II. J Am Coll Cardiol. 2006;47:769-773.
46. Desai H, Aronow WS, Ahn C, et al. Risk factors for appropriate cardio-verter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. Am J Cardiol. 2010;105:1336-1338.
47. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. J Am Coll Cardiol Interv. 2010;3:332-339.
48. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial. Circulation. 2004;110:674-678.
49. Cay S, Cagirci G, Sen N, et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther. 2010;24:41-47.
50. Yun KH, Oh SK, Rhee SJ, et al. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. In press.
51. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009;54:2157-2163.
52. Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009;54:2290-2295.
53. Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (extended-ESTABLISH trial): a follow-up study. Atherosclerosis. 2010;210:497-502.
54. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results from the ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol. 2009;54:558-565.
55. Kulik A, Brookhart MA, Levin R, et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation. 2008;118:1785-1792.
56. Papathanasiou A, Toumpoulis IK, Milionis HJ, et al. Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery. Coron Artery Dis. 2008;19:619-625.
57. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic immune inflammatory response after coronary artery bypass surgery. Crit Care Med. 2006;34:660-667.
58. Dereli Y, Ege E, Kurban S, et al. Preoperative atorvastatin therapy to decrease the systemic immune inflammatory response after coronary artery bypass grafting. J Int Med Res. 2008;36:1248-1254.
59. Berkan O, Katrancioglu N, Ozker E, et al. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. Thorac Cardiovasc Surg. 2009;57:91-95.
60. Porter KE, Naik J, Turner NA, et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002;36:150-157.
61. Fujita H, Banno H, Yamanouchi D, et al. Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. J Surg Res. 2008;148:238-243.
62. Spadaccio C, Pollari F, Casacalenda A, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized controlled study. J Cardiovasc Pharmacol. 2010;55:30-38.
63. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008;29:1548-1559.
64. Magovern JA, Moraca RJ, Bailey SH, et al. Preoperative statin is associated with decreased operative mortality in high-risk coronary artery bypass patients. J Cardiothorac Surg. 2010;5:8.
65. Ouattara A, Benhaoua H, Le Manach Y, et al. Perioperative statin therapy is associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery. J Car-diothorac Vasc Anesth. 2009;23:633-638.
66. Virani SS, Nambi V, Polsani VR, et al. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010;28:80-86.
67. Huffmyer JL, Mauermann WJ, Thiele RH, et al. Preoperative statin administration is associated with lower mortality and decreased need for postop-erative hemodialysis in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2009;23:468-473.
68. Coleman CI, Lucek DM, Hammond J, et al. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin. 2007;23:1783-1790.
69. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg. 1999;15:394-399.
70. Aguilar EM, Miralles Jde H, González AF, et al. In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;37:443-447.
71. Kirk G, McLaren M, Muir AH, et al. Decrease in P-selectin levels in patients with hypercholesterolemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med. 1999;4:23-26.
72. Rajagopalan S, Mckay I, Ford I, et al. Platelet activation increases the severity of peripheral arterial disease: implications for clinical management. J Vasc Surg. 2007;46:485-490.
73. Bulbulia R, Bowman L, Wallendszus K, et al. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645-654.
74. Schanzer A, Hevelone N, Owens CD, et al. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47:774-781.
75. Desai H, Aronow WS, Ahn C, et al. Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing non-cardiac vascular surgery treated with and without statins. Arch Geront Geriat. 2010;51:149-151.
76. Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007;45:936-943.
77. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and at 1 year after treatment. Am J Cardiol. 2003;92:711-712.
78. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholester-olemic patients with peripheral vascular disease. Am J Med. 2003;114:359-364.
79. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorva-statin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-1486.
80. Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadmin-istered amlodipine and atorvastatin in patients with hypertension and dys-lipidemia: results of the AVALON trial. J Clin Hypertens. 2006;8:571-581.
81. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Drugs. 2004;64(suppl 2):43-60.
82. Marino F, Guasti L, Cosentino M, et al. Angiotensin II type I receptor expression in polymorphonuclear lymphocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007; 49:299-305.
83. Lorenzen JM, Neunhöffer H, David S, et al. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension- results from the EUTOPIA trial. Atherosclerosis. 2010;209:184-188.
84. Siński M, Lewandowski J, Ciarka A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hyper-cholesterolaemia and systemic arterial hypertension. Kardiol Pol. 2009;67: 613-620.
85. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin study, a randomized trial. Arch Intern Med. 2008;168:721-727.
86. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007;49: 792-798. (Pubitemid 351664226)
87. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21-26.
88. Schweitzer M, Mitmaker B, Obrand D, et al. Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009;87:915-922.
89. Schweitzer M, Mitmaker B, Obrand D, et al. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovascular Surg. 2010;44:116-122.
90. Kajimoto K, Miyauchi K, Kasai T, et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis. 2009;206:505-511.
91. Sinha S, Frishman WH. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target. J Clin Pharmacol. 1998;38:1077-1088.
92. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg. 2004;28:343-352.
93. McNally MM, Agle SC, Parker FM, et al. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg. 2010;51:1390-1396.
94. Feeney JM, Burns K, Staff I, et al. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg. 2009;209:41-46.
95. Leurs LJ, Visser P, Laheij RJ, et al. Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular. 2006;14:1-8.
96. Sugawara T, Ayer R, Zhang JH. Role of statins in cerebral vasospasm. Acta Neurochir Suppl. 2008;104:287-290.
97. Lapchak PA, Han MK. The 3-hydroxy-3-methyglutaryl A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res. 2009;1303:144-150.
98. Sterzer P, Meintzschel F, Rösler A, et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke. 2001;32:2817-2820.
99. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
100. Naval NS, Abdelhak TA, Zeballos P, et al. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8:6-12.
101. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke. 2008;39:2622-2626.
102. Warshafsky S, Packard D, Marks SJ, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med. 1999;14:763-777.
103. Kandzari DE, Rebeiz AG, Wang A, et al. Contrast nephropathy: an evidence-based approach to prevention. Am J Cardiovasc Drugs. 2003;3:395-405.
104. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843-849.
105. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279-285.
106. Ray JG. Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med. 2003;9:378-384.
107. Agarwal V, Bhardwaj A, Tongbram V, et al. What effect do statins have on the development of venous thromboembolism? A comprehensive meta-analysis of over 900,000 patients. Am J Respir Crit Care Med. 2010;181. Abstract 1936.
108. Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med. 2010;123:60-65.